Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: A CORE diabetes model analysis

Journal of Medical Economics

Volumn 15, Issue SUPPL. 2, 2012, Pages 28-37

  Lee, Won Chan ^a   Samyshkin, Yevgeniy ^a   Langer, Jakob ^b   Palmer, James L ^c  

^a IMS Consulting Group   (United States)

^b NOVO NORDISK INC   (United States)

^c IQVIA   (United States)

Author keywords

Cost effectiveness analysis; Dipeptidyl peptidase 4; Glucagon like peptide 1 receptor agonist; Incretin; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ADD ON THERAPY; ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT OUTCOME; UNITED STATES;

COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MARKOV CHAINS; METFORMIN; OUTCOME ASSESSMENT (HEALTH CARE); PYRAZINES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84867937685     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.716111     Document Type: Article

References (28)

1. Diabetes Statistics. American Diabetes Association 2012. Available at http://www.diabetes.org/diabetes-basics/diabetes-statistics. [Accessed 15 December 2011]
2. National Diabetes Fact Sheet. Centers for Disease Control and Prevention 2012. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf [cited 2011 Dec 15];
3. Byetta Press Release. US Food and Drug Administration 2012. [cited 2011 Dec 15];
4. Januvia Press Release. US Food and Drug Administration 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm 108770.htm. [Accessed 15 December 2011]
5. Onglyza Press Release. US Food and Drug Administration 2012. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm174780. htm. [Accessed 15 December 2011]
6. Linagliptin Press-Release. Boehringer Ingelheim 2012. Available at http://www.boehringer-ingelheim.com/news/news-releases/press-releases/2011/ 03-may-2011-diabetes.html. [Accessed 15 December 2011]
7. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33:511-27
8. Davidson JA. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010;85(12 Suppl):S27-S37
9. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009;124:113-38
10. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
11. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407
12. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59 (Pubitemid 40022410)
13. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Suppl):S27-S40 (Pubitemid 39349906)
14. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
17. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30 (Pubitemid 40360759)
18. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81 (Pubitemid 30090804)
19. Consumer Price Index. United States Department of Labor Bureau of Labor Statistics 2012 February 2A. Available at http://www.bls.gov/cpi/home.htm. [Accessed 4 December 2011]
20. Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin 2011;27:897-906
21. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40 (Pubitemid 27384638)
22. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53 (Pubitemid 41817713)
23. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
24. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9
25. Lee WC, Conner C, Hammer M. Results of a model analysis of the costeffectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther 2010;32:1756-67
26. Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products-liraglutide and exenatide-for the treatment of type 2 diabetes. J Med Econ 2010;13:655-61
27. Bergenstal RM, Daniels G, Mann J, et al. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial: rationale and study design. Diabetes 2011;60(1 Suppl):A612-3
28. Drucker DJ, Sherman SI, Bergenstal RM, et al. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-31